Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression

Publisher： Karger

E-ISSN： 2296-5262|39|10|605-614

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.39, Iss.10, 2016-09, pp. : 605-614

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review

By  

Oncology Research and Treatment, Vol. 36, Iss. 9, 2013-08 ,pp. : 510-518

Karger

Access to resources Recommend Favorite

Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases

By  

Oncology Research and Treatment, Vol. 32, Iss. 11, 2009-10 ,pp. : 674-677

Karger

Access to resources Recommend Favorite

Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?

By  

Oncology Research and Treatment, Vol. 34, Iss. 10, 2011-09 ,pp. : 559-560

Karger

Access to resources Recommend Favorite

Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 35, Iss. 9, 2012-08 ,pp. : 509-513

Karger

Access to resources Recommend Favorite

Long-Term Survival in a Smoking Caucasian Male Patient Treated with Gefitinib for Spinal Cord Compression Secondary to Lung Cancer

By  

Oncology Research and Treatment, Vol. 34, Iss. 6, 2011-05 ,pp. : 326-328

Karger

Access to resources Recommend Favorite